keyword
MENU ▼
Read by QxMD icon Read
search

antiemetics for chemotherapy

keyword
https://www.readbyqxmd.com/read/28633504/a-phase-ii-study-of-palonosetron-aprepitant-dexamethasone-and-olanzapine-for-the-prevention-of-cisplatin-based-chemotherapy-induced-nausea-and-vomiting-in-patients-with-thoracic-malignancy
#1
Kazuhisa Nakashima, Haruyasu Murakami, Kouichi Yokoyama, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Fumie Nishiyama, Mami Kikugawa, Masayo Kaneko, Yumiko Iwamoto, Satomi Koizumi, Keita Mori, Takeshi Isobe, Toshiaki Takahashi
Background: The three-drug combination of a 5-hydroxytryptamine type 3 receptor antagonist, a neurokinin 1 receptor antagonist and dexamethasone is recommended for patients receiving highly emetogenic chemotherapy. However, standard antiemetic therapy is not completely effective in all patients. Methods: We conducted an open-label, single-center, single-arm Phase II study to evaluate the efficacy of olanzapine in combination with standard antiemetic therapy in preventing chemotherapy-induced nausea and vomiting in patients with thoracic malignancy receiving their first cycle of cisplatin-based chemotherapy...
June 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28602709/factors-associated-with-the-use-of-potentially-inappropriate-medications-by-older-adults-with-cancer
#2
Cristiane Moreira Reis, Andrezza Gouvêa Dos Santos, Paula de Jesus Souza, Adriano Max Moreira Reis
OBJECTIVES: To determine the frequency and the factors associated with the use of potentially inappropriate medications (PIMs) by older adults with cancer at an onco-haematology ambulatory clinic of a teaching hospital in Brazil. MATERIAL AND METHODS: Patients aged 60years or older (n=160) subjected to parenteral antineoplastic chemotherapy from May to December 2015 and treated with one or more medications in the ambulatory clinic were interviewed. Data on medications, comorbidities, oncological diagnosis, and functional status were recorded...
June 8, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28595433/managing-chemotherapy-induced-nausea-and-vomiting-in-head-and-neck-cancer-patients-receiving-cisplatin-chemotherapy-with-concurrent-radiation
#3
Jordan Stinson, Kelvin Chan, Justin Lee, Ronald Chow, Paul Cheon, Angie Giotis, Mark Pasetka, Bo Angela Wan, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. METHODS: Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated...
March 21, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28581463/the-burden-of-chemotherapy-induced-nausea-and-vomiting-in-children-receiving-hematopoietic-stem-cell-transplantation-conditioning-a-prospective-study
#4
J Flank, J Sparavalo, H Vol, L Hagen, R Stuhler, D Chong, S Courtney, J J Doyle, A Gassas, T Schechter, L L Dupuis
This prospective study describes chemotherapy-induced nausea and vomiting (CINV) in children (4-18 years) receiving their first hematopoietic stem cell transplant. Emetic episodes, nausea severity (assessed using a validated, self-report nausea severity assessment tool) and antiemetic administration were documented from the start of conditioning until 24 h after the last conditioning agent was administered (acute) and for a further 7 days (delayed). Relationships between CINV control and parenteral nutrition (PN) use and acute gut GvHD (aGvHD) were explored...
June 5, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28503222/olanzapine-for-chemotherapy-induced-nausea-and-vomiting-systematic-review-and-meta-analysis
#5
Legese Chelkeba, Kidu Gidey, Ayele Mamo, Berhane Yohannes, Tsehay Matso, Tsegaye Melaku
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). OBJECTIVE: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV. METHODS: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV...
January 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28501134/factors-associated-with-palliative-care-use-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#6
Rachel S Morris, Faiz Gani, Abdulrahman Y Hammad, Wendy Peltier, T Clark Gamblin, Kiran K Turaga, Fabian M Johnston
BACKGROUND: Peritoneal carcinomatosis represents widespread metastatic disease throughout the abdomen and/or pelvis. Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) improves the overall survival compared to standard therapy alone. The role palliative care (PC) plays however, remains poorly studied among these patients. METHODS: Patients who had previously undergone HIPEC and who underwent an inpatient admission from 7/1/2013 to 6/30/2014 were identified to determine which patients were referred for inpatient or outpatient palliative consultation...
May 1, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28500750/nausea-and-vomiting-in-children-and-adolescents-receiving-intrathecal-methotrexate-a-prospective-observational-study
#7
Jacqueline Flank, Komail Nadeem, Sheliza Moledina, Mila Khanna, Christina Schindera, Angela Punnett, L Lee Dupuis
BACKGROUND: The prevalence of nausea and vomiting after receipt of intrathecal methotrexate (IT-MTX) in pediatric oncology patients is unknown. METHODS: Patients (4-18 years) about to receive IT-MTX were eligible to participate in this prospective, observational study. Patients received antiemetics as prescribed by their clinical team. Nausea severity (patient-assessed), timing of emetic episodes, and administration of antiemetics were recorded beginning immediately prior to IT-MTX administration, for the next 24 hr (acute phase), and for a maximum of 7 additional days (delayed phase)...
May 13, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28486012/adherence-to-and-implementation-of-asco-antiemetic-guidelines-in-routine-practice-in-a-tertiary-cancer-center-in-india
#8
Vijay M Patil, Vanita Noronha, Amit Joshi, Anant Ramaswamy, Sudeep Gupta, Arvind Sahu, Vipul Doshi, Tarachand Gupta, Sushmita Rath, Shripad Banavali, Kumar Prabhash
BACKGROUND: Nonadherence of antiemetic prescriptions to evidence-based antiemetic guidelines is associated with an increased proportion of chemotherapy-induced nausea and vomiting. The current project was carried out to improve the quality of antiemetic prescriptions at our institute. METHODS: We initially performed a retrospective analysis of 1,211 consecutive antiemetic prescription records of adult patients with solid tumors who received outpatient chemotherapy regimens...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28470980/aprepitant-and-fosaprepitant-drug-interactions-a-systematic-review
#9
Priya Patel, J Steven Leeder, Micheline Piquette-Miller, L Lee Dupuis
AIMS: Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepitant and describes adverse events ascribed to drug interactions with aprepitant or fosaprepitant. METHODS: We systematically reviewed the literature to September 11, 2016 to identify articles evaluating drug interactions involving aprepitant/fosaprepitant...
May 4, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28447301/management-of-chemotherapy-induced-nausea-and-vomiting-in-pediatric-patients
#10
REVIEW
Rudolph M Navari
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment. This review summarizes the safety and efficacy of current antiemetic agents for the prevention of CINV in children. Information on antiemetic prophylaxis for CINV in children was obtained from a literature review of current peer-reviewed articles and recent international guidelines. The literature review and the international antiemetic guidelines provide recommendations for use of specific antiemetics in children based on the emetogenicity of the chemotherapy...
June 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28427442/effect-of-acupuncture-in-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-advanced-cancer-study-protocol-for-a-randomized-controlled-trial
#11
Qi-Wei Li, Ming-Wei Yu, Guo-Wang Yang, Xiao-Min Wang, Huan Wang, Chen-Xi Zhang, Na Xue, Wei-Ru Xu, Qi Fu, Zhong Yang, Lin Yang
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side effects in patients with cancer. The introduction and development of antiemetic drugs have significantly improved the ability of clinicians to control CINV, but it is not easy to translate to practical application, owing to financial issues, provider-related barriers, and patient factors. Nondrug therapies are needed to alleviate the symptoms of CINV. Acupuncture is an appropriate adjunctive treatment for CINV, but additional evidence is needed...
April 20, 2017: Trials
https://www.readbyqxmd.com/read/28418944/the-benefit-of-pro-re-nata-antiemetics-provided-with-guideline-consistent-antiemetics-in-delayed-nausea-control
#12
Sun Young Rha, Joohyuk Sohn, Gun Min Kim, Hye Ryun Kim, Jiyeon Lee
BACKGROUND: Delayed nausea after chemotherapy remains a symptom of interest. Clinicians often provide additional and/or pro re nata (p.r.n.) antiemetics with guideline-consistent antiemetics in an attempt to achieve further symptom control. Whether the usage of additional and/or p.r.n. antiemetics provide added benefit remains as a question. OBJECTIVE: The purpose of this study was to determine the benefit of providing additional antiemetics and/or p.r.n. antiemetics with guideline-consistent antiemetics in the control of nausea, functioning, and quality of life (QOL)...
April 17, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28396308/new-options-and-controversies-in-the-management-of-chemotherapy-induced-nausea-and-vomiting
#13
Sara M Koth, Jill Kolesar
PURPOSE: An expanding array of options for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), including regimens containing olanzapine or recently approved neurokinin 1 (NK1) receptor antagonists, are reviewed. SUMMARY: Up to 80% of patients receiving chemotherapy have CINV. Current practice guidelines recommend that patients treated with highly emetogenic chemotherapy also receive a 3-drug antiemetic regimen initiated on the day of and continued for 3 days after chemotherapy administration, with the most commonly used 3-drug regimen consisting of an NK1 receptor antagonist, a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, and dexamethasone...
June 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28395603/chemotherapy-induced-nausea-and-vomiting-cinv-in-190-colorectal-cancer-patients-a-prospective-registration-study-by-the-cinv-study-group-of-japan
#14
Yasushi Tsuji, Hideo Baba, Koji Takeda, Michiya Kobayashi, Eiji Oki, Masahiro Gotoh, Kazuhiro Yoshida, Mototsugu Shimokawa, Yoshihiro Kakeji, Keisuke Aiba
OBJECTIVES: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. METHODS: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC)...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28376213/neurokinin-1-receptor-antagonist-based-triple-regimens-in-preventing-chemotherapy-induced-nausea-and-vomiting-a-network-meta-analysis
#15
Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases...
February 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28373467/efficacy-of-single-dose-first-generation-5-ht3-receptor-antagonist-and-dexamethasone-for-preventing-nausea-and-vomiting-induced-by-low-dose-carboplatin-based-chemotherapy
#16
Daizo Kaito, Hirotoshi Iihara, Norihiko Funaguchi, Junki Endo, Fumitaka Ito, Komei Yanase, Sayaka Toyoshi, Yuka Sasaki, Chiemi Hirose, Natsumi Arai, Mika Kitahora, Yasushi Ohno, Yoshinori Itoh, Shinya Minatoguchi
BACKGROUND: Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the weekly administration of CBDCA (area under the curve (AUC) 2 mg/ml/min) and paclitaxel (PTX: 40 mg/m(2)) is frequently applied as standard therapy. However, the optimal antiemetic measures in the use of such low-dose CBDCA remain unclear...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28365889/antiemetic-therapy-for-non-anthracycline-and-cyclophosphamide-moderately-emetogenic-chemotherapy
#17
REVIEW
Naoki Inui
Although antiemetic management in cancer therapy has improved, chemotherapy-induced nausea and vomiting remain common and troubling adverse events. Chemotherapeutic agents are classified based on their emetogenic effects, and appropriate antiemetics are recommended according to this categorization. Chemotherapy categorized as moderately emetogenic is associated with a wide spectrum of emetic risks. Combined anthracycline and cyclophosphamide regimens have been recently reclassified as highly emetogenic chemotherapy regimen...
May 2017: Medical Oncology
https://www.readbyqxmd.com/read/28362229/late-chronotypes-are-associated-with-neoadjuvant-chemotherapy-induced-nausea-and-vomiting-in-women-with-breast-cancer
#18
Kwang-Min Lee, Doo-Young Jung, Heesung Hwang, Won-Hyoung Kim, Joo-Young Lee, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, David Spiegel, Bong-Jin Hahm
Neoadjuvant chemotherapy, that is, the administration of chemotherapy before surgery, has been commonly used for locally advanced breast cancer to improve the surgical outcomes and increase the opportunity for breast-conserving therapy. Women with breast cancer often receive an anthracycline-based regimen as the neoadjuvant chemotherapy, which is associated with a high risk of emesis. Despite the development of novel antiemetics, chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as a major adverse effect, affecting the quality of life of the patients...
2017: Chronobiology International
https://www.readbyqxmd.com/read/28327932/integrated-safety-analysis-of-rolapitant-with-coadministered-drugs-from-phase-ii-iii-trials-an-assessment-of-cyp2d6-or-bcrp-inhibition-by-rolapitant
#19
S Barbour, T Smit, X Wang, D Powers, S Arora, V Kansra, M Aapro, J Herrstedt
Background: Rolapitant, a long-acting neurokinin (NK)1 receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK1 RAs, rolapitant does not inhibit or induce cytochrome P450 (CYP) 3A4, but it does inhibit CYP2D6 and breast cancer resistance protein (BCRP). To analyze potential drug-drug interactions between rolapitant and concomitant medications, this integrated safety analysis of four double-blind, randomized phase II or III studies of rolapitant examined adverse events (AEs) by use versus non-use of drug substrates of CYP2D6 or BCRP...
June 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28281050/a-cost-utility-analysis-of-risk-model-guided-versus-physician-s-choice-antiemetic-prophylaxis-in-patients-receiving-chemotherapy-for-early-stage-breast-cancer-a-net-benefit-regression-approach
#20
Kednapa Thavorn, Doug Coyle, Jeffrey S Hoch, Lisa Vandermeer, Sasha Mazzarello, Zhou Wang, George Dranitsaris, Dean Fergusson, Mark Clemons
PURPOSE: We assessed the cost-effectiveness of a risk model-guided (RMG) antiemetic prophylaxis strategy compared with the physician's choice (PC) strategy in patients receiving chemotherapy for early-stage breast cancer. METHODS: We conducted a cost-utility analysis based on a published randomized controlled trial of 324 patients with early-stage breast cancer undergoing chemotherapy at two Canadian cancer centers. Patients were randomized to receive their antiemetic treatments according to either predefined risk scores or the treating physician's preference...
March 9, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"